<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36411653</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>In FUS[1-359]-tg mice O,S-dibenzoyl thiamine reduces muscle atrophy, decreases glycogen synthase kinase 3 beta, and normalizes the metabolome.</ArticleTitle><Pagination><StartPage>113986</StartPage><MedlinePgn>113986</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2022.113986</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(22)01375-0</ELocationID><Abstract><AbstractText>Mutations in the gene encoding the RNA/DNA-binding protein Fused in Sarcoma (FUS) have been detected in familial amyotrophic lateral sclerosis (ALS) patients. FUS has been found to be a critical component of the oxidative damage repair complex that might explain its role in neurodegeneration. Here, we examined what impact antioxidant treatment with thiamine (vitamine B1), or its more bioavailable derivative O,S-dibenzoylthiamine (DBT), would have on the hallmarks of pathology in the FUS[1-359]-transgenic mouse model of ALS. From 8-weeks old, in the pre-symptomatic phase of disease, animals received either thiamine, DBT (200&#xa0;mg/kg/day), or vehicle for 6 weeks. We examined physiological, behavioral, molecular and histological outcomes, as well as the serum metabolome using nuclear magnetic resonance (NMR). The DBT-treated mice displayed improvements in physiological outcomes, motor function and muscle atrophy compared to vehicle, and the treatment normalized levels of brain glycogen synthase kinase-3&#x3b2; (GSK-3&#x3b2;), GSK-3&#x3b2; mRNA and IL-1&#x3b2; mRNA in the spinal cord. Analysis of the metabolome revealed an increase in the levels of choline and lactate in the vehicle-treated FUS mutants alone, which is also elevated in the cerebrospinal fluid of ALS patients, and reduced glucose and lipoprotein concentrations in the FUS[1-359]-tg mice, which were not the case in the DBT-treated mutants. The administration of thiamine had little impact on the outcome measures, but it did normalize circulating HDL levels. Thus, our study shows that DBT therapy in FUS mutants is more effective than thiamine and highlights how metabolomics may be used to evaluate therapy in this model.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Probert</LastName><ForeName>Fay</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Oxford University, Mansfield Road, OX1 3QT Oxford, UK; Department of Chemistry, Oxford University, Mansfield Road, OX1 3TA Oxford, UK. Electronic address: fay.probert@chem.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorlova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Trubetskaya str. 8-2, 119991 Moscow, Russia; Laboratory of Cognitive Dysfunctions, Institute of General Pathology and Pathophysiology, Baltiyskaya str. 8, 125315 Moscow, Russia. Electronic address: anna.gorlova204@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deikin</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Joint Center for Genetic Technologies and Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Pobedy str. 85, 308015 Belgorod, Russia. Electronic address: alexei@deikin.ru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bettendorff</LastName><ForeName>Lucien</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology, GIGA-Neurosciences, University of Li&#xe8;ge, av Hippocrate 1, 13-4000 Li&#xe8;ge, Belgium. Electronic address: L.Bettendorff@uliege.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veniaminova</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Trubetskaya str. 8-2, 119991 Moscow, Russia. Electronic address: katya.veniaminova@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedorubov</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Trubetskaya str. 8-2, 119991 Moscow, Russia. Electronic address: nedorubov.ras@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaprov</LastName><ForeName>Kirill D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Joint Center for Genetic Technologies and Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Pobedy str. 85, 308015 Belgorod, Russia; Institute of Physiologically Active Compounds RAS, Severniy pr. 1, 142432 Chernogolovka, Russia. Electronic address: chapkir@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanova</LastName><ForeName>Tamara A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds RAS, Severniy pr. 1, 142432 Chernogolovka, Russia. Electronic address: tamar-ivanova@yandex.ru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anthony</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Oxford University, Mansfield Road, OX1 3QT Oxford, UK. Electronic address: daniel.anthony@pharm.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strekalova</LastName><ForeName>Tatyana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Trubetskaya str. 8-2, 119991 Moscow, Russia; Laboratory of Cognitive Dysfunctions, Institute of General Pathology and Pathophysiology, Baltiyskaya str. 8, 125315 Moscow, Russia; Maastricht University, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Universiteitssingel 40, NL 6229 Maastricht, the Netherlands. Electronic address: t.strekalova@maastrichtuniversity.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>8PUY50JWLU</RegistryNumber><NameOfSubstance UI="C023638">bentiamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X66NSO3N35</RegistryNumber><NameOfSubstance UI="D013831">Thiamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013831" MajorTopicYN="N">Thiamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Fused in Sarcoma protein</Keyword><Keyword MajorTopicYN="N">Lactate</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Thiamine</Keyword></KeywordList><CoiStatement>Conflict of interest statement Here, we declare that none of the authors involved in the work have any competing interest. We confirm that founding bodies had no role in the data collection, manuscript preparation and decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36411653</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2022.113986</ArticleId><ArticleId IdType="pii">S0753-3322(22)01375-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>